Impact of ACE-i and ARBs for patients with COVID-19

Impact of ACE-i and ARBs for patients with COVID-19 - تاثیر داروهای ضدفشارخون بر کووید19
Low blood pressure, or hypotension, in COVID-19 patients with a history of hypertension appears to be a risk factor for kidney damage and death.
Reducing hypertension medications if and when COVID-19 patients become hypotensive could prevent acute kidney injury and death, according to a new study.
COVID-19 patients previously taking the blood pressure-lowering drugs angiotensin-converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) are more likely to die than those who were not taking the medications.
It is important to note that patients taking ACE-i and/or ARBs may have more advanced cardiovascular disease or other chronic health conditions that further increase the risk for serious complications of COVID-19.
Release date: 10 September 2020

Source: American Heart Association